Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure
文献类型：期刊论文
| 作者 | Qiu, CB; Qiu, CS; Hess, P; Clozel, JP; Clozel, M |
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2001-06 |
| 卷号 | 22期号:6页码:541-548 |
| 关键词 | endothelins endothelin receptors tezosentan angiotensin-converting enzyme inhibitors myocardial infarction congestive heart failure hemo-dynamics enalapril |
| ISSN号 | 0253-9756 |
| 文献子类 | Article |
| 英文摘要 | AIM: To evaluate the acute effects of tezosentan, a new dual parenteral endothelin receptor antagonist, on hemodynamics in a rat model of chronic heart failure (CHF), and further investigated if the combination of tezosentan with the angiotensin converting enzyme (ACE) inhibitor, enalapril, had additive hemodynamic effect. METHODS: Hemodynamics was measured in rats with CHF, induced by ligation of the left coronary artery. RESULTS: At 3 to 5 weeks after myocardial infarction, rats developed CHF. This was evidenced by a marked increase in left ventricular end-diastolic pressure (LVEDP) with mean values of 23 to 26 mmHg, by a 30 % to 40 % reduction in left ventricular dp/dt(max) and by a more than 10 % decrease in mean arterial pressure (MAP) as compared to sham-operated rats. In CHF rats, acute intravenous administration of either tezosentan (10 mg kg-l) or enalapril (1 mg . kg(-1)) markedly decreased MAP and LVEDP, without affecting heart rate or dp/dt(max). Tezosentan had additive effects on MAP and LVEDP when given with enalapril compared with tezosentan (P < 0.05) or enalapril (P < 0.05) alone. There were no significant changes in heart rate and dp/dt(max) with the combination treatment compared with tezosentan- or enalapril-treated CHF rats. CONCLUSION: Acute intravenous tezosentan improves cardiac hemodynamics and decreases LVEDP and afterload (MAP) without changes in heart rate and cardiac contractility (dp/dt(max)) in CHF mts. These favorable effects of tezosentan are similar to those of enalapril. Furthermore, the benefits of tezosentan are apparent in addition to ACE inhibition. Thus, tezosentan could be a useful therapeutic agent in the acute treatment of heart failure. |
| WOS关键词 | VASOCONSTRICTION ; ANTAGONIST ; PROGRESSION ; ACTIVATION ; CAPTOPRIL ; SURVIVAL ; BOSENTAN ; THERAPY |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000169174700012 |
| 出版者 | ACTA PHARMACOLOGICA SINICA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/274485]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Qiu, CB |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol, Shanghai 200031, Peoples R China 2.Actel Ltd, CH-4123 Allschwil, Switzerland |
| 推荐引用方式 GB/T 7714 | Qiu, CB,Qiu, CS,Hess, P,et al. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure[J]. ACTA PHARMACOLOGICA SINICA,2001,22(6):541-548. |
| APA | Qiu, CB,Qiu, CS,Hess, P,Clozel, JP,&Clozel, M.(2001).Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.ACTA PHARMACOLOGICA SINICA,22(6),541-548. |
| MLA | Qiu, CB,et al."Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure".ACTA PHARMACOLOGICA SINICA 22.6(2001):541-548. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。